Tento interní projekt je určen na podporu přípravy návrhu projektu H2020 s názvem AmylS, 0164/2015 (ID=47826). Projekt postoupil do druhého kola, výzva NMP 12-2015. Projekt připravuje konsorcium vedené univerziotou v Boloni, která je stabilně vysoce úspěšná v získávání evropských grantů. Při přípravě návrhu využívá konsorcium spolupráci a renomovanou a úspěšnou agenturou AMIRES.

ABSTRAKT PŘIPRAVOVANÉHO PROJEKTU.

The main aim of AmylS is to develop a biomaterial platform based on biospecific magnetic nanovehicles for the treatment and monitoring of Alzheimer's disease (AD). The project aims to bring a novel solution to the current treatments of AD by an unique combination of well-established technologies;
The goal of the AmylS is the conceptual enhancement of the therapeutic strength of the available drugs and remedies. The claimed enhancement will proceed via the development of a strongly multifunctional nanovehicle enabled with functionalities of (A) accurate magnetic guiding, (B) high recognition selectivity, (C) drug release after the penetration of BBB, and all this enormously supported by the (D) in vivo imaging and monitoring of the process via MRI on superparamagnetic nanoparticles, working additionally as a powerful contrast agent. Drug/antibody loaded nanovehicles able to bind B-amyloid to aid diagnosis of AD and operate as a high potential therapeutic tool able to penetrate BBB will act directly on the target place.
AmylS will focuses on detection and identification of amyloid plaques, using our nanovehicle as negative contrast agents for MRI. There are numerous potential advantages to Magnetic Resonance Imaging (MRI) based amyloid imaging methods, lower cost, more widespread availability and greater ease of use for AD models. Noteworthy, AmylS will improve spatial resolution of MRI, without need of radioligands. The project will develop from in silico (computer modelling), to in vitro (2D and 3D culture systems) and in vivo (live imaging and MNPs effects on animals) studies, thus setting all conditions for scaling-up the process.
AmylS relevance to the call is based on its flexible use of a surface functionalization methodology that will enhance the delivery of accepted drugs, thus supporting current therapeutics while adding smart driving and biospecificity to a theranostic, minimally-invasive procedure.